Kingsclere villagers petition to save village chemist
Kingsclere villagers and councillors are petitioning to keep the village chemist in the face of government cuts, Newbury Today reports.
At a recent meeting of Kingsclere Parish Council, vice-chairman Mick Farey warned that the Government was reducing funding for community pharmacies, which provide a vital service for the elderly.
He said: “It could result in 3,000 small pharmacies closing.
“Anything we can do as a council and village to support the retention of our facilities we need to do.”
Cuts to pharmacies could hit Lincolnshire hardest
Pharmacies in Lincolnshire could be the worst hit in the country by government cuts, it has been claimed, the Lincolnshire Echo reports.
Up and down the country, pharmacies are having to manage cuts of six per cent to their budget for this year.
Chris Kenny of Watsons pharmacy in Lincoln said: "In Lincolnshire there are fewer pharmacies per head of population so the cuts will hit Lincolnshire pharmacies more than perhaps elsewhere."
Watsons is one of many pharmacies in the county trying to cope with the cuts, which it has been claimed could lead to one in four high street pharmacies closing across the country according to campaigners.
There's a warning Lincolnshire could be one of the hardest hit by government cuts to pharmacies. pic.twitter.com/y1rOMnRai8
— Radio Lincolnshire (@BBCRadioLincs) March 15, 2016
Newry pharmacist saved nut allergy chef after anaphylaxis attack at carvery
A relaxing lunch out on Saturday afternoon turned into a terrifying near-death experience for Newry man Aaron McDonald, who suffers from a severe nut allergy, the Belfast Telegraph reports.
As he tucked into his carvery, the 25-year-old trained chef did not realise there were traces of nuts in his food.
Within seconds he went anaphylactic shock, which causes the throat to close over.
He had forgotten to take his life-saving EpiPen with him and was moments from death when a newly graduated pharmacist saved his life.
'It was life or death'-Newly-graduated pharmacist saves chef's life after nut allergy attack https://t.co/huIoAPixWa pic.twitter.com/PPQiBhbeFJ
— Independent.ie (@Independent_ie) March 15, 2016
Drug made from cannabis to treat childhood epilepsy
A cannabis-based drug has successfully treated epileptic children, raising hopes for the medical potential of the plant, The Times reports.
Children with a rare form of epilepsy had a 39 per cent reduction in seizures when given the drug, which experts hope will now become the first treatment for the condition.
About 40,000 children in Britain have epilepsy, with many having frequent seizures.
Epidiolex uses the compound cannabidiol, a component of cannabis that is not psychoactive. It is thought to modulate signalling mechanisms in the brain and reduce nerve inflammation.
A groundbreaking study using synthetic cannabis to treat severe childhood epilepsy is about to start in Melbourne... https://t.co/0M6QYu1NXZ
— Lifestyle Radio (@LifestyleRadio) February 4, 2016
'Cold turkey' best way to quit smoking, study shows
People who want to quit smoking are more likely to succeed if they go "cold turkey" by stopping abruptly, a study in Annals of Internal Medicine shows, the BBC reports.
Volunteers who used this approach were 25% more likely to remain abstinent half a year from the date that they give up than smokers who tried to gradually wean themselves off instead.
The NHS says that picking a convenient date to quit is important. Make a promise, set a date and stick to it, it advises.
It may be tough going cold turkey, but it is the best way to ##QuitSmoking and improve your health https://t.co/cQqhgS2GUZ (via @bbchealth)
— Clinical Cardiology (@ClinicalCardio) March 15, 2016
AstraZeneca debates linking executive pay with revenue targets
AstraZeneca has opened the door to a rethink on linking executive pay to the ambitious sales targets it sets in place to ward off Pfizer, the US company that launched a bid for it two years ago, The Times reports.
Pascal Soriot, the FTSE 100 drugmaker’s chief executive, outlined a plan in 2014 to boost sales to $45billion by 2023, a 70% increase.
Some investors have called for his long-term bonus to be linked to the revenue target, leaving the company facing a bruising encounter with shareholders at its annual meeting next month.
Astrazeneca chief Pascal Soriot faces £3.5m pay revolt following profit warning
https://t.co/9VNXwgklTy— No More Excuses (@NoMoreExcuses_) March 14, 2016
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.